1. A 68-year-old man with Parkinson's disease has been stable on pramipexole immediate-release 1.5 mg three times daily for 3 years. His creatinine clearance (CrCl) at the time of initiation was 52 mL/min, placing him just above the threshold for dose reduction. Repeat renal function testing now shows his CrCl has declined to 28 mL/min. Which of the following correctly describes how his pramipexole regimen must be adjusted and why?
A) No dose adjustment is required because pramipexole undergoes sufficient hepatic metabolism to compensate for reduced renal clearance, and plasma concentrations remain stable across the CrCl range of 15 to 50 mL/min
B) Because pramipexole is eliminated almost entirely by renal excretion as unchanged drug, its clearance falls as CrCl declines; a drop from 52 to 28 mL/min therefore requires a substantial reduction in his maximum daily dose and retitration from a lower starting point, with the degree of reduction set by his current CrCl per the prescribing information
C) A modest stepwise reduction applied from his current 1.5 mg three times daily is sufficient, because the dose appropriate for any new CrCl is determined relative to the patient's prior dose rather than relative to the recommended maximum for that level of renal function
D) Pramipexole should be discontinued immediately and replaced with ropinirole, which does not require renal dose adjustment, because any CrCl below 30 mL/min is an absolute contraindication to pramipexole use
E) The dose adjustment required depends on whether the patient is experiencing adverse effects at his current dose; if he is tolerating 1.5 mg three times daily without nausea or somnolence, no pharmacokinetic adjustment is needed regardless of CrCl
ANSWER: B
Rationale:
Pramipexole is eliminated almost entirely by renal excretion as unchanged drug, with less than 10% undergoing hepatic metabolism. Its clearance is therefore directly and proportionally dependent on creatinine clearance, and the required adjustment is driven by renal function rather than by clinical tolerance. A fall in CrCl from 52 to 28 mL/min represents a substantial decline in clearance, so continuing 1.5 mg three times daily would allow the drug to accumulate to potentially toxic plasma concentrations. The correct approach is to reduce his maximum daily dose substantially and retitrate upward from an appropriate lower starting point, with the specific dose ceiling for his current CrCl taken from the prescribing information. The adjustment is keyed to his current level of renal function, not derived as a fixed step down from his prior dose. Option B is correct.
Option A: Option A is incorrect because pramipexole does not undergo sufficient hepatic metabolism to compensate for reduced renal clearance; its bioavailability is approximately 90% precisely because first-pass hepatic extraction is minimal, and renal excretion is the dominant and nearly exclusive elimination pathway.
Option C: Option C is incorrect because the appropriate dose at a given CrCl is defined relative to the recommended maximum for that level of renal function, not as a step down from whatever the patient happened to be taking; applying a modest reduction from his elevated baseline dose would leave him above the recommended ceiling for a CrCl of 28 mL/min.
Option D: Option D is incorrect because a CrCl below 30 mL/min is not an absolute contraindication to pramipexole; the drug can be used with appropriate dose reduction in this range, and while switching to ropinirole is a valid clinical option, it is not mandated by the pharmacokinetics.
Option E: Option E is incorrect because dose adjustment for pramipexole in renal impairment is pharmacokinetically mandated regardless of symptom tolerance; a patient may tolerate an excess dose without overt symptoms while accumulating drug to toxic plasma concentrations, and renal-function-based dose caps exist for this reason.
2. A 61-year-old woman with Parkinson's disease is stable on ropinirole 4 mg three times daily. Over the same two-week period, her psychiatrist adds fluvoxamine for obsessive-compulsive disorder and she successfully quits smoking with varenicline. Three weeks later she develops severe nausea, dizziness, and somnolence. Her ropinirole dose has not been changed. Which of the following best explains the magnitude of her toxicity, and what is the appropriate management?
A) Fluvoxamine and varenicline both inhibit renal tubular secretion of ropinirole through competing for organic cation transporters, producing additive renal accumulation of the drug; the correct response is to switch from ropinirole to pramipexole, which uses a different renal transport mechanism
B) Varenicline partially agonizes nicotinic acetylcholine receptors, increasing dopaminergic tone in the mesolimbic system and pharmacodynamically amplifying ropinirole's adverse effects without changing its plasma concentration; the correct response is to discontinue varenicline
C) Fluvoxamine inhibits CYP1A2, raising ropinirole plasma concentrations, while smoking cessation simultaneously activates CYP1A2, lowering them — the two effects cancel, and the toxicity must therefore be explained by varenicline's direct dopaminergic mechanism rather than a pharmacokinetic interaction
D) Both fluvoxamine (a potent CYP1A2 inhibitor) and smoking cessation (removal of CYP1A2 induction by polycyclic aromatic hydrocarbons) independently raise ropinirole plasma concentrations by reducing CYP1A2-mediated metabolism; occurring simultaneously, their effects are additive, producing a substantially larger rise in ropinirole exposure than either event alone — ropinirole dose reduction is required
E) Fluvoxamine induces CYP1A2 as a hepatic enzyme inducer, increasing ropinirole clearance and lowering plasma concentrations, while smoking cessation independently lowers concentrations further; the combined effect produces ropinirole under-dosing, and the symptoms represent a paradoxical withdrawal-like dopaminergic deficiency state
ANSWER: D
Rationale:
Ropinirole is metabolized primarily by CYP1A2. Two independent pharmacokinetic events occurred simultaneously in this patient. First, fluvoxamine is one of the most potent CYP1A2 inhibitors in clinical use, capable of increasing ropinirole plasma concentrations by up to 80% through inhibition of first-pass and systemic hepatic metabolism. Second, cigarette smoke contains polycyclic aromatic hydrocarbons that induce CYP1A2; during active smoking, this induction had been accelerating ropinirole clearance and maintaining lower plasma concentrations than would be seen in a non-smoker at the same dose. When smoking cessation removes the CYP1A2 inducer, enzyme activity returns toward uninduced baseline, further slowing ropinirole metabolism and raising concentrations. Both events independently reduce CYP1A2 activity relative to the patient's prior induced state, and occurring together they produce an additive and substantial rise in ropinirole plasma concentrations, explaining the severity of toxicity at an unchanged dose. The correct response is ropinirole dose reduction. Option D is correct.
Option A: Option A is incorrect because ropinirole is not significantly eliminated by renal tubular secretion; it is hepatically cleared via CYP1A2, and organic cation transporter competition is not the mechanism of this interaction.
Option B: Option B is incorrect because varenicline's partial nicotinic agonism does not pharmacodynamically amplify ropinirole's adverse effects in a clinically significant way; the toxicity is pharmacokinetic — elevated ropinirole plasma concentrations — not a pharmacodynamic sensitization from varenicline.
Option C: Option C is incorrect because the directionality of both effects is the same, not opposing: both fluvoxamine inhibition of CYP1A2 and removal of CYP1A2 induction by smoking cessation reduce CYP1A2 activity relative to the prior induced state, both raise ropinirole concentrations, and their effects are additive rather than canceling.
Option E: Option E is incorrect because fluvoxamine is a CYP1A2 inhibitor, not an inducer; it reduces ropinirole clearance and raises plasma concentrations, producing toxicity rather than deficiency.
3. A 70-year-old woman with Parkinson's disease has stage 4 chronic kidney disease (CrCl 22 mL/min) and Child-Pugh class B hepatic impairment from alcohol-related cirrhosis. Her neurologist is selecting a dopamine agonist and considers rotigotine transdermal patch because it does not require renal dose adjustment. Which of the following correctly characterizes the suitability of rotigotine in this patient with dual organ impairment?
A) Rotigotine requires no renal dose adjustment because it is not renally eliminated as unchanged drug — it undergoes extensive hepatic metabolism; however, this hepatic dependence means that severe hepatic impairment warrants caution and careful dose titration, making rotigotine a suboptimal choice in this patient with Child-Pugh class B cirrhosis despite its renal safety
B) Rotigotine is the ideal agent for this patient because transdermal delivery completely bypasses both renal and hepatic elimination; drug absorbed through the skin is excreted unchanged in sweat, making organ function irrelevant to dosing decisions
C) Rotigotine requires renal dose adjustment for CrCl below 30 mL/min because its active metabolites accumulate in renal impairment and cause dopaminergic toxicity; it is therefore contraindicated in this patient on the same pharmacokinetic basis as pramipexole
D) Rotigotine is preferred in this patient because severe hepatic impairment induces CYP enzymes that accelerate rotigotine metabolism, paradoxically reducing systemic exposure and lowering the risk of adverse effects at standard doses
E) Rotigotine and pramipexole carry identical risks in this patient because both are eliminated entirely by renal excretion as unchanged drug; the transdermal route of rotigotine does not alter its ultimate elimination pathway
ANSWER: A
Rationale:
Rotigotine is delivered transdermally, bypassing gastrointestinal absorption and first-pass hepatic metabolism. However, once absorbed into the systemic circulation, rotigotine undergoes extensive hepatic metabolism through CYP-mediated conjugation, with metabolites excreted in both urine and feces. Because its elimination is hepatically dependent, rotigotine does not require renal dose adjustment — renal excretion of unchanged drug is not a meaningful elimination pathway. This makes it a rational choice in patients with renal impairment alone. However, in this patient with concurrent Child-Pugh class B hepatic impairment, rotigotine's hepatic dependence becomes clinically relevant: severe hepatic impairment reduces the clearance of hepatically metabolized drugs, potentially causing rotigotine accumulation. While rotigotine is not formally contraindicated in hepatic impairment, prescribing information advises caution and careful titration in severe hepatic disease, and this patient's dual organ impairment makes her a particularly challenging case requiring individualized risk-benefit assessment. Option A is correct.
Option B: Option B is incorrect because rotigotine is not excreted unchanged in sweat; transdermal delivery affects the route of absorption, not the route of elimination. After systemic absorption, rotigotine is metabolized by the liver and eliminated via urine and feces as metabolites — organ function remains relevant to drug clearance regardless of the absorptive route.
Option C: Option C is incorrect because rotigotine's metabolites do not accumulate to cause dopaminergic toxicity in renal impairment in a clinically established manner requiring mandatory dose reduction; the renal dose-adjustment requirement described is that of pramipexole, not rotigotine.
Option D: Option D is incorrect because severe hepatic impairment impairs, not induces, CYP enzyme activity; cirrhosis reduces hepatic metabolic capacity, slowing drug clearance and increasing systemic exposure — the opposite of what option D describes.
Option E: Option E is incorrect because rotigotine and pramipexole do not share identical elimination pathways; pramipexole is renally cleared as unchanged drug, while rotigotine is hepatically metabolized — these are fundamentally different elimination routes with different implications for dose adjustment in organ impairment.
4. A neurologist explains to a resident that continuous subcutaneous apomorphine infusion (CSAI) not only reduces off time in advanced Parkinson's disease but also reduces dyskinesias — even though apomorphine is itself a potent dopamine agonist. The resident finds this counterintuitive, since dyskinesias are generally considered a consequence of excessive dopaminergic stimulation. Which of the following best explains the mechanism by which CSAI reduces dyskinesias?
A) Apomorphine selectively downregulates D1 receptors in the striatum during continuous infusion, reducing the direct-pathway overactivation that generates dyskinesias while preserving D2-mediated indirect pathway inhibition
B) The subcutaneous route of apomorphine delivery bypasses the nigrostriatal pathway entirely, producing motor benefit through spinal dopamine receptors that do not generate dyskinesias when chronically stimulated
C) CSAI reduces dyskinesias by allowing substantial reduction in concurrent levodopa dose; since levodopa is the primary driver of dyskinesias through pulsatile striatal stimulation, reducing the levodopa dose alone accounts for the improvement in dyskinesias, and apomorphine's receptor profile plays no mechanistic role
D) Apomorphine suppresses the serotonergic component of dyskinesia generation in the raphe-striatal pathway through a direct serotonergic action, reducing dyskinesia amplitude without affecting the underlying dopaminergic motor drive
E) Dyskinesias arise from pulsatile, intermittent receptor stimulation — the pattern produced by oral immediate-release levodopa — that drives maladaptive synaptic plasticity and receptor sensitization in the striatum; CSAI replaces this pulsatile pattern with continuous, stable dopaminergic stimulation at D1, D2, D3, and D4 receptors, suppressing the sensitization process and reducing dyskinesia expression
ANSWER: E
Rationale:
Levodopa-induced dyskinesias arise not simply from dopaminergic stimulation per se, but from the pulsatile, on-and-off pattern of receptor activation produced by oral immediate-release levodopa. Each dose produces a sharp rise in striatal dopamine followed by a trough, and this oscillating receptor stimulation drives maladaptive synaptic plasticity and sensitization — particularly at D1 receptors in the direct pathway — that manifests clinically as dyskinesias. Continuous dopaminergic stimulation, by contrast, stabilizes receptor occupancy and suppresses the sensitization process. CSAI delivers apomorphine at a constant rate over 12 to 16 waking hours, replacing pulsatile stimulation with continuous D1, D2, D3, and D4 receptor activation. This normalization of stimulation pattern reduces dyskinesia expression even though the total dopaminergic input is maintained or increased. The concurrent reduction in oral levodopa dose that CSAI permits also contributes, but the mechanism is not solely levodopa reduction — the continuous stimulation pattern itself is dyskinesia-suppressive. Option E is correct.
Option A: Option A is incorrect because apomorphine does not selectively downregulate D1 receptors during continuous infusion; receptor downregulation in this manner has not been established as the mechanism of dyskinesia reduction with CSAI, and selective D1 downregulation would impair motor efficacy as well.
Option B: Option B is incorrect because apomorphine does not bypass the nigrostriatal pathway or act primarily through spinal dopamine receptors; it acts at striatal postsynaptic D1 and D2 receptors, and the subcutaneous route refers to the absorptive route, not a distinct anatomical target.
Option C: Option C is incorrect because while levodopa dose reduction contributes to dyskinesia improvement with CSAI, the continuous stimulation pattern of apomorphine itself has anti-dyskinetic properties independent of levodopa dose reduction; option C overstates the role of levodopa reduction and dismisses the mechanistic contribution of continuous receptor stimulation.
Option D: Option D is incorrect because apomorphine's anti-dyskinetic benefit during continuous infusion is a dopaminergic receptor-level phenomenon arising from continuous rather than pulsatile stimulation; it is not produced by a direct serotonergic action on a raphe-striatal pathway.
5. Pergolide was withdrawn from the US market in 2007 after echocardiographic surveillance revealed fibrotic valvulopathy in a substantial proportion of treated patients — the same cardiac lesion previously associated with fenfluramine, the appetite suppressant withdrawn in 1997. A cardiologist asks what the shared mechanism is and what it implies about the structural specificity of this adverse effect. Which of the following best answers this question?
A) Both pergolide and fenfluramine block cardiac L-type calcium channels in valve interstitial cells, causing intracellular calcium depletion that leads to fibroblast apoptosis and subsequent fibrotic repair tissue replacing normal valve architecture
B) Both pergolide and fenfluramine inhibit serotonin reuptake transporters in cardiac valve endothelial cells, causing local serotonin accumulation that activates multiple receptor subtypes nonspecifically and produces a generalized inflammatory valvulopathy
C) Both pergolide and fenfluramine activate 5-HT2B receptors on cardiac valve interstitial fibroblasts; 5-HT2B receptor activation in these cells stimulates fibroblast proliferation and collagen deposition, producing a restrictive valvulopathy with regurgitation that is mechanistically and pathologically identical between the two drugs — confirming that the valvular injury is 5-HT2B-mediated and not specific to either drug's primary pharmacological target
D) Both drugs cause valvulopathy through a shared off-target effect on dopamine D4 receptors expressed in cardiac valve fibroblasts, explaining why non-ergot dopamine agonists with D4 activity such as rotigotine also carry a valvulopathy risk comparable to ergot agents
E) The shared mechanism is alpha-adrenergic receptor activation in the coronary vasculature, producing recurrent ischemic episodes that cause cumulative fibrous replacement of valve leaflets — a mechanism confirmed by the complete prevention of valvulopathy with concurrent alpha-blocker therapy
ANSWER: C
Rationale:
The valvulopathy caused by both pergolide and fenfluramine is mechanistically identical: both drugs activate 5-HT2B receptors expressed on interstitial fibroblasts of the cardiac valves. 5-HT2B receptor stimulation in these cells triggers mitogenic signaling, fibroblast proliferation, and excess collagen deposition, producing a restrictive valvulopathy with regurgitation that is pathologically indistinguishable between the two drugs. This mechanistic identity is highly informative: it establishes that the valve injury is a class effect of 5-HT2B agonism rather than a unique property of either fenfluramine or ergot alkaloids, and it predicts that any drug with significant 5-HT2B agonist activity carries this cardiac risk. This is precisely why non-ergot dopamine agonists — which lack 5-HT2B activity at therapeutic concentrations — do not produce this valvulopathy. Option C is correct.
Option A: Option A is incorrect because L-type calcium channel blockade is not the mechanism of valvulopathy for either drug; L-type calcium channel blockers are a separate drug class used therapeutically in cardiovascular disease and do not cause fibrotic valvulopathy through fibroblast apoptosis or fibrotic repair.
Option B: Option B is incorrect because neither pergolide nor fenfluramine are serotonin reuptake inhibitors; fenfluramine causes serotonin release and reuptake inhibition, but the valve pathology is specifically 5-HT2B receptor-mediated, not a consequence of nonspecific serotonin accumulation activating multiple receptor subtypes.
Option D: Option D is incorrect because the shared mechanism is 5-HT2B receptor activation, not D4 receptor activity; rotigotine does not carry a valvulopathy risk comparable to ergot agents — it lacks 5-HT2B agonist activity at therapeutic concentrations, which is the essential distinction between ergot and non-ergot agonists.
Option E: Option E is incorrect because alpha-adrenergic receptor activation in the coronary vasculature is not the mechanism of drug-induced valvulopathy for either agent; ischemia-driven fibrous valve replacement is a distinct pathological process not caused by ergot agonists or fenfluramine through this mechanism.
6. A 63-year-old woman was diagnosed with Parkinson's disease two years ago and started on ropinirole monotherapy using an agonist-first strategy, given her age and preserved cognition at diagnosis. At her current visit, neuropsychological testing reveals mild cognitive impairment — new since her baseline assessment. She also reports increased daytime sleepiness and two recent episodes of confusion. Her motor control on ropinirole remains adequate. Which of the following best describes the appropriate reassessment of her treatment strategy and its rationale?
A) Her cognitive impairment and somnolence are likely caused by the underlying Parkinson's disease process rather than ropinirole, since cognitive decline is an expected feature of PD progression; the agonist-first strategy should be maintained because discontinuing ropinirole would accelerate motor deterioration without addressing the cognitive symptoms
B) The emergence of cognitive impairment, excessive somnolence, and confusion in a patient on a dopamine agonist represents a shift in the risk-benefit calculation: the adverse effects of agonist therapy now carry greater risk in this patient than they did at initiation, and the clinical threshold for transitioning to levodopa — which is better tolerated cognitively — has been crossed; ropinirole should be gradually reduced and levodopa introduced
C) The appropriate response is to add a cholinesterase inhibitor such as rivastigmine to treat her cognitive impairment while continuing ropinirole unchanged, as cognitive symptoms in PD on agonist therapy are best managed pharmacologically rather than by altering the dopaminergic regimen
D) Because her motor control remains adequate on ropinirole, dose reduction is contraindicated — any reduction in agonist dose risks acute motor deterioration that would outweigh the modest cognitive benefit; the agonist-first strategy should continue until the patient herself requests a change
E) She should be switched immediately from ropinirole to rotigotine transdermal patch, which has a different receptor profile including 5-HT1A partial agonism that protects against dopamine agonist-induced cognitive decline and is specifically recommended in patients who develop cognitive impairment on oral agonists
ANSWER: B
Rationale:
The decision to initiate an agonist-first strategy is not irreversible — it requires ongoing reassessment as the patient's clinical profile evolves. The rationale for agonist-first in younger patients rests on a specific risk-benefit balance: the dyskinesia-delay benefit outweighs the agonist adverse effect risks in cognitively intact patients. However, this balance shifts when cognitive impairment, excessive somnolence, or confusion emerge during agonist therapy. Dopamine agonists — particularly through D3 mesolimbic receptor activity — contribute to cognitive worsening, somnolence, and hallucinations in vulnerable patients. The appearance of these adverse effects signals that this patient has crossed the threshold at which agonist risks outweigh the remaining dyskinesia-prevention benefit. Levodopa is better tolerated cognitively than dopamine agonists and should be introduced as ropinirole is gradually reduced, with careful monitoring of motor function during the transition. Option B is correct.
Option A: Option A is incorrect because while Parkinson's disease itself causes cognitive decline, dopamine agonists are a recognized contributor to cognitive worsening, somnolence, and confusion — distinguishing drug effect from disease progression requires considering the temporal relationship between agonist initiation and symptom emergence, and the appropriate response is a therapeutic trial of dose reduction or transition, not attribution solely to disease progression.
Option C: Option C is incorrect because adding a cholinesterase inhibitor without addressing the likely agonist contribution to cognitive symptoms treats the symptom while leaving the probable cause in place; the first step is to reduce or discontinue the agonist, not to add a cognitive agent.
Option D: Option D is incorrect because adequate motor control on ropinirole does not preclude dose reduction; dopamine agonist dose reduction can often be managed without acute motor deterioration if done gradually and with concurrent levodopa introduction, and maintaining a dose that is causing cognitive harm is not justified by adequate motor efficacy alone.
Option E: Option E is incorrect because rotigotine does not have established evidence for protecting against dopamine agonist-induced cognitive decline; its 5-HT1A partial agonism is a pharmacological distinction but has not been demonstrated to reduce cognitive adverse effects relative to ropinirole in clinical practice, and a class switch within dopamine agonists would not be the recommended approach when agonist adverse effects have become clinically significant.
7. A 55-year-old man with Parkinson's disease on pramipexole develops severe pathological gambling that causes significant financial harm. His neurologist reduces the pramipexole dose, but each attempt at reduction precipitates unacceptable motor deterioration — his parkinsonism is too severe to tolerate the dose reduction required for ICD control. Which of the following represents the most pharmacologically rational advanced management strategy in this situation?
A) Add naltrexone, an opioid receptor antagonist, to block the reward reinforcement of gambling behavior while maintaining the pramipexole dose; naltrexone is first-line pharmacotherapy for dopamine agonist-induced impulse control disorders in patients who cannot tolerate dose reduction
B) Switch from pramipexole to cabergoline, which has lower D3 receptor affinity and therefore a lower intrinsic ICD risk, allowing the motor benefit to be maintained without the mesolimbic reward pathway overactivation that drives gambling behavior
C) Add a selective serotonin reuptake inhibitor (SSRI) to suppress the compulsive component of the gambling behavior through 5-HT reuptake inhibition in the prefrontal cortex, while maintaining pramipexole at the dose required for motor control
D) Deep brain stimulation (DBS) of the subthalamic nucleus can improve motor function sufficiently to allow substantial reduction in pramipexole dose; by reducing the agonist dose to a level that no longer drives ICD-level D3 mesolimbic overactivation, DBS provides a pathway to ICD control that is not available through dose reduction alone
E) The patient should be referred for cognitive behavioral therapy (CBT) targeting gambling urges; CBT has been shown in randomized trials to fully suppress dopamine agonist-induced ICDs without requiring any change in dopaminergic therapy, making medication adjustment unnecessary in motivated patients
ANSWER: D
Rationale:
When impulse control disorders cannot be managed through dopamine agonist dose reduction because motor function is too severely impaired at lower doses, deep brain stimulation (DBS) of the subthalamic nucleus represents a pharmacologically rational advanced management strategy. DBS improves motor function in Parkinson's disease through a mechanism independent of dopaminergic receptor stimulation — modulation of basal ganglia circuit activity through high-frequency electrical stimulation. This improvement in motor control allows the total dopaminergic medication burden, including the pramipexole dose, to be substantially reduced postoperatively. By reducing the agonist dose to a level that no longer drives pathological D3 mesolimbic receptor overactivation in the nucleus accumbens, DBS creates the pharmacological space for ICD control that dose reduction alone could not achieve. This strategy is specifically recognized in clinical guidelines for refractory ICD in patients who cannot tolerate agonist dose reduction. Option D is correct.
Option A: Option A is incorrect because naltrexone is not established first-line pharmacotherapy for dopamine agonist-induced ICDs; while there is limited evidence for opioid receptor antagonism in ICD management, it has not been shown to fully suppress agonist-driven ICDs without dose modification, and the reward mechanism of dopamine agonist-induced ICDs is primarily dopaminergic rather than opioid-mediated.
Option B: Option B is incorrect because cabergoline is an ergot agonist with significant 5-HT2B receptor activity and a fibrotic valvulopathy risk; it is specifically restricted for PD use in most guidelines and should not be initiated as an alternative dopamine agonist regardless of its D3 affinity profile.
Option C: Option C is incorrect because SSRIs do not reliably suppress dopamine agonist-induced ICDs through serotonergic reuptake inhibition; the primary driver of the ICD is D3-mediated mesolimbic reward pathway overactivation, which is not adequately attenuated by serotonergic modulation alone, and adding an SSRI without reducing the agonist dose leaves the underlying pharmacological trigger in place.
Option E: Option E is incorrect because while CBT may provide some benefit as an adjunct for behavioral management of ICD in PD, it has not been demonstrated in randomized trials to fully suppress dopamine agonist-induced ICDs without any change in dopaminergic therapy; CBT is a supportive strategy, not a substitute for addressing the pharmacological cause.
8. A pharmacology student asks how the apomorphine–ondansetron interaction should be understood and managed, given that ondansetron is an effective antiemetic in most other settings. Which of the following best describes what is established about this interaction and the appropriate clinical response?
A) Co-administration of apomorphine with ondansetron (or any other 5-HT3 antagonist) has been associated with profound hypotension and loss of consciousness, and the combination is contraindicated; the precise mechanism is not fully established, but the empirical risk is sufficient to prohibit 5-HT3 antagonists in apomorphine-treated patients, and domperidone — which lacks 5-HT3 antagonist activity — is the antiemetic of choice instead
B) The interaction is fully explained by ondansetron inhibiting CYP3A4, the enzyme responsible for apomorphine metabolism, causing apomorphine plasma concentrations to rise; the elevated apomorphine then blocks cardiac hERG potassium channels through structural similarity to quinidine, so the safe response is simply to lower the apomorphine dose and continue ondansetron
C) The interaction is fully explained by apomorphine's D2 receptor agonism in the cardiac conduction system combined with ondansetron's muscarinic M2 receptor blockade in the sinoatrial node; because the mechanism is dopaminergic, ondansetron may be continued safely if a beta-blocker is added
D) The interaction is fully explained by ondansetron switching to 5-HT4 receptor activation in cardiac tissue once 5-HT3 receptors are occupied by apomorphine, increasing cAMP and prolonging the action potential; this is a predictable and manageable effect that does not require avoiding 5-HT3 antagonists
E) The interaction is fully explained by ondansetron inhibiting the cardiac sinus node If current while apomorphine's dopaminergic activity lowers the threshold for If-mediated bradycardia; the appropriate response is cardiac pacing rather than avoidance of the drug combination
ANSWER: A
Rationale:
The co-administration of apomorphine with ondansetron, or with any other 5-HT3 antagonist, has been associated with profound hypotension and loss of consciousness in reported cases, and the combination is contraindicated. The important teaching point is that this contraindication rests on the observed clinical risk, not on a fully established mechanism: the precise pharmacological basis for the severe hypotension has not been definitively characterized, and it should not be presented to learners as settled. What is clinically actionable is unambiguous — 5-HT3 antagonists as a class must be avoided in patients receiving apomorphine, regardless of how effective they are as antiemetics in other settings. Domperidone, a peripherally acting D2 antagonist that does not cross the blood-brain barrier and lacks 5-HT3 antagonist activity, is the antiemetic of choice for apomorphine initiation, started before the first dose and continued through titration. Option A is correct because it states the established empirical contraindication and the correct management while appropriately declining to assert an unproven mechanism.
Option B: Option B is incorrect because ondansetron does not inhibit CYP3A4 to a clinically meaningful degree, and hERG blockade through quinidine-like structure is not an established explanation for this interaction; more importantly, the management it recommends — continuing ondansetron at a lower apomorphine dose — is unsafe, because 5-HT3 antagonists are contraindicated with apomorphine outright.
Option C: Option C is incorrect because ondansetron has no clinically significant muscarinic antagonist activity, the proposed dopaminergic mechanism is not established, and the recommended management of continuing ondansetron with a beta-blocker is unsafe; the combination must be avoided rather than co-managed.
Option D: Option D is incorrect because ondansetron is a selective 5-HT3 antagonist without meaningful 5-HT4 activity, the receptor-switching mechanism is pharmacologically unfounded, and the conclusion that 5-HT3 antagonists need not be avoided directly contradicts the established contraindication.
Option E: Option E is incorrect because ondansetron does not inhibit the cardiac If current — that action characterizes ivabradine — the proposed mechanism is not established, and the recommended response of cardiac pacing rather than avoidance is inappropriate for a combination that is simply contraindicated.
9. A 72-year-old man with Parkinson's disease has both stage 4 chronic kidney disease (CrCl 19 mL/min) and Child-Pugh class B hepatic cirrhosis. His neurologist must select a dopamine agonist. Which of the following correctly characterizes why no non-ergot agonist is straightforwardly safe in this patient, and what the prescribing approach should be?
A) Pramipexole is the safest choice because its renal elimination pathway is unaffected by hepatic cirrhosis, and dose reduction for his level of renal impairment provides a sufficient safety margin for combined organ impairment without additional monitoring
B) Ropinirole is the safest choice because its hepatic CYP1A2 metabolism is upregulated in chronic kidney disease, compensating for any reduction in hepatic clearance caused by cirrhosis and maintaining stable plasma concentrations without dose adjustment
C) All three non-ergot agonists are equally contraindicated in combined renal and hepatic impairment; dopamine agonist therapy should be deferred until renal and hepatic function recover to at least Child-Pugh class A and CrCl above 50 mL/min
D) Rotigotine is straightforwardly safe in this patient because transdermal delivery eliminates any dependence on either renal or hepatic function for drug elimination, making organ impairment irrelevant to dosing decisions regardless of severity
E) Each non-ergot agonist carries a specific organ-impairment liability: pramipexole is renally eliminated and accumulates in CKD; ropinirole is hepatically cleared via CYP1A2 and accumulates in hepatic impairment; rotigotine is also hepatically metabolized and requires caution in severe hepatic disease despite no renal adjustment requirement — no agent is free of concern in this patient, and the decision requires careful individualized risk-benefit assessment with lower starting doses, slower titration, and close monitoring
ANSWER: E
Rationale:
Each non-ergot dopamine agonist has a primary elimination pathway that creates a specific liability in this patient with combined organ impairment. Pramipexole is eliminated almost entirely by renal excretion as unchanged drug; in this patient with CrCl 19 mL/min, substantial dose reduction is mandatory and accumulation risk is high. Ropinirole is cleared primarily by hepatic CYP1A2 metabolism; Child-Pugh class B cirrhosis reduces hepatic metabolic capacity, slowing ropinirole clearance and raising plasma concentrations at standard doses. Rotigotine, while avoiding the need for renal dose adjustment, is also hepatically metabolized — severe hepatic impairment impairs its clearance as well, and prescribing information advises caution in this setting. No agent is free of pharmacokinetic concern in this patient, and the clinical approach requires individualized selection based on the relative severity of each organ impairment, starting at the lowest feasible dose, titrating slowly, and monitoring closely for adverse effects. Option E is correct.
Option A: Option A is incorrect because pramipexole's renal elimination pathway is its liability in this patient, not its safety advantage; while its elimination is indeed independent of hepatic function, the CKD itself creates a significant accumulation risk requiring mandatory dose reduction, and the combined organ impairment does not simplify prescribing.
Option B: Option B is incorrect because CYP1A2 activity is not upregulated in chronic kidney disease; renal and hepatic functions are regulated independently, and CKD does not compensate for hepatic CYP1A2 impairment caused by cirrhosis.
Option C: Option C is incorrect because dopamine agonist therapy is not categorically contraindicated in all combined organ impairment — patients with advanced PD may have no viable alternative, and the appropriate response is careful dose adjustment and monitoring, not deferral until organ function improves to thresholds that may be unachievable.
Option D: Option D is incorrect because transdermal delivery does not eliminate dependence on hepatic function for drug elimination; rotigotine is absorbed transdermally and then eliminated by hepatic metabolism — the route of absorption does not change the route of elimination, and severe hepatic impairment impairs rotigotine clearance regardless of how it enters the systemic circulation.
10. A resident asks why dopamine agonists with half-lives of 8 to 12 hours produce substantially fewer dyskinesias than immediate-release levodopa over the first several years of treatment, even when the two strategies produce equivalent motor benefit. Which of the following best integrates the pharmacokinetic and pharmacodynamic mechanisms underlying this difference?
A) Dopamine agonists produce fewer dyskinesias than immediate-release levodopa because agonists act exclusively at D2 receptors, whereas levodopa-derived dopamine activates both D1 and D2 receptors; D1 receptor activation is the sole driver of dyskinesia, and its absence with agonist therapy eliminates dyskinesia risk entirely during the initial years of treatment
B) Dopamine agonists produce fewer dyskinesias because they are converted to levodopa in peripheral tissues at a slow, sustained rate that mimics physiological dopamine synthesis, whereas administered levodopa enters the brain rapidly and causes sudden supraphysiological dopamine surges that dyskinesias require to develop
C) Immediate-release levodopa produces pulsatile peaks and troughs in striatal dopamine receptor occupancy, driving maladaptive synaptic plasticity and sensitization — particularly at D1 receptors in the direct pathway — through repeated cycles of over-stimulation and withdrawal; dopamine agonists with 8-to-12-hour half-lives produce more continuous, stable receptor occupancy that avoids this sensitization process, substantially reducing dyskinesia induction over the first several years of therapy
D) Dopamine agonists produce fewer dyskinesias because their lower intrinsic efficacy at D2 receptors relative to dopamine itself means they cannot fully activate the receptor signaling cascades required for the aberrant corticostriatal plasticity that underlies dyskinesia; levodopa-derived dopamine, as a full agonist with higher intrinsic efficacy, readily crosses the threshold for dyskinesia induction
E) The difference in dyskinesia rates reflects differences in peripheral metabolism rather than central receptor pharmacology; immediate-release levodopa produces high concentrations of peripheral dopamine metabolites that enter the brain and sensitize striatal neurons non-specifically, whereas dopamine agonists do not generate these peripheral metabolites and therefore do not sensitize the striatum to dyskinesia
ANSWER: C
Rationale:
The key mechanistic insight is that dyskinesias in Parkinson's disease arise not from dopaminergic stimulation per se, but from the pulsatile, oscillating pattern of receptor activation produced by short-acting oral immediate-release levodopa. Each dose of IR levodopa produces a sharp rise in striatal dopamine followed by a trough as the dose is metabolized, creating repeated cycles of receptor overstimulation and withdrawal. This pulsatile pattern drives maladaptive synaptic plasticity — particularly sensitization of D1 receptor signaling in the direct basal ganglia pathway through FosB accumulation and glutamatergic synaptic remodeling — that ultimately manifests as dyskinesias. Dopamine agonists with half-lives of 8 to 12 hours produce more sustained, stable plasma concentrations and consequently more continuous striatal receptor occupancy, avoiding the peaks and troughs that trigger this sensitization process. This pharmacokinetic difference — continuous versus pulsatile stimulation — is the primary mechanistic basis for the lower dyskinesia rates with agonist therapy in the first several years of treatment. Option C is correct.
Option A: Option A is incorrect because dopamine agonists are not devoid of D1 activity in all cases — rotigotine and apomorphine do have D1 activity — and the mechanism of dyskinesia reduction is the continuous stimulation pattern, not the absence of D1 activation; furthermore, describing D1 activation as the sole driver eliminating dyskinesia risk entirely with agonists overstates the pharmacological basis.
Option B: Option B is incorrect because dopamine agonists are not converted to levodopa in peripheral tissues; they act directly at dopamine receptors without requiring biosynthetic conversion, and the mechanism of lower dyskinesia rates is pharmacokinetic stability, not peripheral conversion mimicking physiological synthesis.
Option D: Option D is incorrect because the lower dyskinesia induction with agonists is not explained by lower intrinsic efficacy at D2 receptors — dopamine agonists used in PD are effective agonists, not partial agonists with markedly reduced intrinsic efficacy, and the mechanism is the continuous versus pulsatile stimulation pattern rather than intrinsic receptor efficacy differences.
Option E: Option E is incorrect because peripheral dopamine metabolites are not the mechanism of striatal sensitization; levodopa is converted to dopamine in the brain by surviving nigrostriatal terminals and administered aromatic amino acid decarboxylase, and the sensitization mechanism is central receptor-level, not driven by peripheral metabolite brain penetration.
11. A movement disorder specialist is evaluating a 46-year-old man with young-onset Parkinson's disease who takes levodopa 2,200 mg daily — nearly three times his prescribed dose of 800 mg. He obtains extra doses from family members, takes them compulsively throughout the day, and has developed severe dyskinesias. He refuses dose reduction, insisting the higher doses are necessary for function, though his motor state is objectively worsened by the excess. A colleague suggests that his self-escalation reflects underprescribing — that his prescribed dose is simply inadequate. Which of the following correctly distinguishes dopamine dysregulation syndrome (DDS) from underprescribing, and identifies the appropriate management approach?
A) The colleague is correct: objective motor worsening at the patient's self-selected dose confirms that the dose is supraoptimal and clinically harmful, but this finding is equally consistent with underprescribing in a patient with rapid disease progression who needs further evaluation before attributing the behavior to DDS
B) DDS is distinguished from underprescribing by the presence of dyskinesias and objective motor deterioration at the self-administered dose — findings that confirm the dose is supraoptimal and pharmacologically excessive rather than insufficient; management requires a structured dose-reduction program combined with behavioral support and psychiatric co-management, not dose escalation to the self-selected level
C) DDS cannot be clinically distinguished from underprescribing without a levodopa dose-response challenge; the correct initial management is to formally increase the prescribed dose to match the patient's self-selected level and observe whether motor function improves or worsens, using the response to guide diagnosis
D) The presence of dyskinesias confirms underprescribing in this patient — dyskinesias in young-onset PD always indicate insufficient dopaminergic coverage because young patients have higher striatal dopamine receptor density and require supranormal doses to achieve adequate receptor occupancy; the prescribed dose of 800 mg is therefore clearly inadequate regardless of the patient's behavior
E) DDS is distinguished from underprescribing exclusively by the patient's subjective experience — patients with DDS report euphoria and stimulant-like effects from excess doses, while underprescribed patients report only motor improvement; because this patient reports functional necessity rather than euphoria, DDS cannot be diagnosed and underprescribing is more likely
ANSWER: B
Rationale:
Dopamine dysregulation syndrome and underprescribing can be definitively distinguished by the objective clinical findings at the self-administered dose. In a patient who is underprescribed, taking a higher dose than prescribed produces motor improvement — the patient's motor function is better at the higher dose than at the prescribed dose. In DDS, the patient takes dopaminergic medications far in excess of the dose required for motor control, driven by hedonic and stimulant-like effects in the mesolimbic system; at the self-administered excess dose, motor function is objectively worsened by dyskinesias and the deteriorated motor state that accompanies peak-dose toxicity. This patient has severe dyskinesias and objective motor deterioration at 2,200 mg — not motor improvement — confirming that his self-selected dose is supraoptimal and pharmacologically excessive. This rules out underprescribing and establishes DDS. Management requires a structured dose-reduction program to bring the levodopa dose toward the therapeutic range, combined with behavioral support and psychiatric co-management given the addiction-like pathophysiology; dose escalation to the patient's self-selected level would worsen his clinical state and reinforce the compulsive behavior. Option B is correct.
Option A: Option A is incorrect because objective motor worsening at the self-administered dose is not consistent with underprescribing; underprescribing produces motor improvement as dose rises, not deterioration — the presence of dyskinesias and worsening function at the current dose confirms pharmacological excess.
Option C: Option C is incorrect because a dose-response challenge escalating to the patient's self-selected dose is not indicated and would be clinically harmful; the objective findings already distinguish DDS from underprescribing without requiring further dose escalation.
Option D: Option D is incorrect because dyskinesias in young-onset PD do not confirm underprescribing; dyskinesias are a recognized consequence of excessive dopaminergic stimulation, not insufficient coverage, and are a hallmark of DDS, not of inadequate dosing — the reasoning in option D inverts the clinical interpretation.
Option E: Option E is incorrect because DDS is not diagnosed exclusively by subjective reports of euphoria; the compulsive medication-seeking behavior, dose self-escalation against medical advice, and objective harm from the excess — including dyskinesias and motor deterioration — are the diagnostic criteria, and patients with DDS frequently deny or rationalize the behavior as medically necessary rather than reporting euphoria.
12. A 68-year-old man with Parkinson's disease maintained on pramipexole oral therapy is switched to rotigotine transdermal patch perioperatively so that dopaminergic therapy can be continued through an NPO period. His surgery proceeds uneventfully, and he is cleared to resume oral medications on the morning of postoperative day 2. Which of the following correctly describes how the transition back to oral pramipexole should be managed to avoid pharmacokinetic complications?
A) The rotigotine patch should be removed 24 hours before the first oral pramipexole dose to allow complete rotigotine washout; oral pramipexole is then started at a low dose and retitrated from the beginning, since returning to the pre-surgical dose immediately risks overstimulation from residual rotigotine
B) The rotigotine patch can remain in place for up to 72 hours after the first oral pramipexole dose without risk of double-dosing, because rotigotine and pramipexole act at different receptor subtypes — rotigotine at D1/D2/D3/D4 and pramipexole at D2/D3 — and there is no pharmacodynamic overlap between them at therapeutic doses
C) Oral pramipexole should be resumed at the pre-surgical dose on postoperative day 2, and the rotigotine patch should be left in place until it expires naturally over the next 12 to 24 hours; the gradual decline in rotigotine delivery as the patch depletes provides a smooth transition without clinical consequence
D) When oral medications resume, the first oral pramipexole dose should be administered and the rotigotine patch removed simultaneously; removing the patch at the time of the first oral dose prevents a period of double-dosing while ensuring continuity of dopaminergic coverage without a gap between the two formulations
E) The rotigotine patch should be removed the night before oral medications are resumed, and oral pramipexole should begin the following morning at half the pre-surgical dose; the half-dose strategy is required because pramipexole's renal clearance is transiently reduced in the immediate postoperative period, necessitating a conservative restart regardless of pre-surgical renal function
ANSWER: D
Rationale:
Rotigotine transdermal patch delivers drug continuously at a stable rate; when the patch is removed, plasma concentrations decline gradually over several hours as residual drug in the skin depot is absorbed and then cleared. The correct transition strategy when resuming oral dopaminergic therapy is to administer the first oral dose and remove the patch simultaneously. This approach ensures continuity — there is no gap in dopaminergic coverage — while preventing a period of double-dosing that would occur if the patch were left in place after oral therapy resumed. Removing the patch immediately before or at the moment of the first oral dose is the clinically recommended transition method. Option D is correct.
Option A: Option A is incorrect because a 24-hour washout period before the first oral dose is not required and is not recommended; removing the patch 24 hours early would create an unacceptable gap in dopaminergic therapy in a patient with Parkinson's disease, risking acute motor deterioration.
Option B: Option B is incorrect because rotigotine and pramipexole do have pharmacodynamic overlap — both act at D2 and D3 receptors — and leaving the patch in place for 72 hours after starting oral pramipexole would produce a prolonged period of combined dopaminergic exposure from both formulations, increasing the risk of nausea, somnolence, hypotension, and other dose-related adverse effects.
Option C: Option C is incorrect because leaving the rotigotine patch in place while oral pramipexole is restarted at the full pre-surgical dose allows the patch to continue delivering rotigotine during the initial period of oral pramipexole dosing, creating a double-dosing interval; a depleting patch does not provide a smooth transition — it continues to deliver drug until removed, not until it runs out of drug.
Option E: Option E is incorrect because transient postoperative renal impairment is not a universal indication to restart pramipexole at half the pre-surgical dose; postoperative renal function should be assessed and dose adjustment applied if CrCl has declined, but a universal half-dose restart is not the standard recommendation, and removing the patch the night before oral resumption creates an unnecessary gap in therapy.
13. A 78-year-old man with Parkinson's disease has persistent visual hallucinations and paranoid delusions despite agonist dose reduction and an adequate trial of quetiapine at optimized doses. His neurologist considers escalating to clozapine. Which of the following correctly describes the pharmacological rationale for clozapine's superiority over quetiapine in refractory PD psychosis, and the mandatory safety monitoring program that accompanies its use?
A) Clozapine has the lowest D2 receptor affinity of any available antipsychotic, producing effective antipsychotic activity through non-D2 mechanisms — including antagonism at muscarinic, histaminergic, and serotonergic receptors — while producing minimal striatal D2 blockade and therefore less motor worsening than quetiapine; its use requires enrollment in a Risk Evaluation and Mitigation Strategy (REMS) program with mandatory absolute neutrophil count (ANC) monitoring — weekly for 6 months, biweekly for the following 6 months, then monthly — due to the risk of potentially fatal agranulocytosis
B) Clozapine is preferred over quetiapine because it selectively blocks D4 receptors in the limbic system without any D2 blockade in the striatum or limbic system; D4 selectivity eliminates both motor worsening and the metabolic adverse effects seen with quetiapine, and no hematological monitoring is required because agranulocytosis is a historical concern resolved by the current clozapine formulation
C) Clozapine is superior to quetiapine in PD psychosis because it crosses the blood-brain barrier more rapidly, achieving therapeutic antipsychotic concentrations in the limbic system within minutes of administration, whereas quetiapine requires 4 to 6 weeks of steady-state accumulation before antipsychotic effects emerge in PD patients
D) The rationale for clozapine escalation is that quetiapine blocks 5-HT2A receptors preferentially, and treatment-refractory PD psychosis is specifically driven by 5-HT2A receptor overactivation that requires D2 blockade for resolution; clozapine's higher D2 receptor affinity relative to quetiapine provides the additional D2 blockade needed for antipsychotic efficacy without clinically significant motor worsening
E) Clozapine is preferred in refractory PD psychosis because it induces CYP3A4 in the striatum, accelerating the metabolism of excess dopamine at postsynaptic receptors and normalizing dopaminergic tone without requiring receptor blockade; its REMS program monitors for hepatotoxicity rather than hematological toxicity
ANSWER: A
Rationale:
Clozapine occupies a unique position among antipsychotics in Parkinson's disease because it has the lowest D2 receptor affinity of any agent in this class. Its antipsychotic efficacy is mediated predominantly through antagonism at non-D2 receptors — including muscarinic M1/M4, histamine H1, and serotonin 5-HT2A receptors — rather than through striatal D2 blockade. This low D2 occupancy profile means clozapine produces effective antipsychotic activity with minimal worsening of motor function in PD, making it the most appropriate agent when quetiapine has failed. However, clozapine carries a risk of potentially fatal agranulocytosis in approximately 1 to 2% of patients. Because of this risk, clozapine use in the United States requires enrollment in the Clozapine REMS program, with mandatory absolute neutrophil count monitoring: weekly for the first 6 months, biweekly for the following 6 months, and monthly thereafter once stable. Dispensing is contingent on current monitoring results. Option A is correct.
Option B: Option B is incorrect because clozapine does not selectively block D4 receptors — it has a broad multi-receptor pharmacology — and the agranulocytosis risk is not a historical artifact resolved by current formulations; it remains a current, real, and potentially fatal risk requiring the full REMS monitoring program for all patients on clozapine regardless of formulation.
Option C: Option C is incorrect because clozapine's superiority over quetiapine in PD psychosis is pharmacodynamic — related to its receptor profile and D2 occupancy — not related to blood-brain barrier penetration speed; and quetiapine does not require 4 to 6 weeks of accumulation before antipsychotic effects emerge.
Option D: Option D is incorrect because the rationale for clozapine escalation is not higher D2 receptor affinity relative to quetiapine — in fact, clozapine has lower D2 affinity than quetiapine — and treatment-refractory PD psychosis is not specifically driven by 5-HT2A receptor overactivation requiring D2 blockade for resolution.
Option E: Option E is incorrect because clozapine does not induce CYP3A4 in the striatum or accelerate dopamine metabolism; this is a pharmacologically invented mechanism with no basis in established pharmacology, and the REMS program monitors for agranulocytosis through ANC testing, not for hepatotoxicity.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.